{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:18:03Z","timestamp":1787026683952,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Liver fibrosis monitoring is essential in patients with chronic hepatitis B (CHB). However, less robust, noninvasive diagnostic methods for staging liver fibrosis, other than liver biopsy, are available. Our previous study demonstrated a panel of cellular proteins recognized by autoantibodies that may have potential value in discrimination of CHB and liver cirrhosis. We aim to assess the diagnostic value of these serum autoantibodies for staging liver fibrosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Candidate autoantigens were screened and assessed by microarray analysis in 96 healthy controls and 227 CHB patients with pre-treatment biopsy-proven METAVIR fibrosis score, comprising 69, 115, and 43 cases with S0-1, S2-3, and S4 stages, respectively. Autoantibodies with potential diagnostic value for staging liver fibrosis were verified by enzyme-linked immunosorbent assays (ELISA). Receiver operating characteristic curve was conducted to evaluate autoantibody performance.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Microarray analysis identified autoantigens CENPF, ACY1, HSPA6, and ENO1 with potential diagnostic value for liver fibrosis staging, among which CENPF and ACY1 were validated using ELISA. CENPF and ACY1 autoantibodies had area under the curve values of 0.746 and 0.685, 58.14 and 74.42% sensitivity, and 88.41 and 60.87% specificity, respectively, for discriminating liver fibrosis stages S4 and S0-1. The prevalence of CENPF and ACY1 autoantibodies was not correlated with age, sex or level of inflammation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Autoimmune responses may be elicited during progression of liver fibrosis, and serum autoantibodies may be a valuable biomarker for staging liver fibrosis deserving of further study.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2021.807087","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T03:04:51Z","timestamp":1641265491000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification and Validation of Novel Serum Autoantibodies Biomarkers for Staging Liver Fibrosis in Patients With Chronic Hepatitis B"],"prefix":"10.3389","volume":"8","author":[{"given":"Saiping","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0140-6736(09)62195-4","article-title":"Non-invasive assessment of liver fibrosis: are we ready?","volume":"375","author":"Castera","year":"2010","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1373\/clinchem.2004.032227","article-title":"Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C","volume":"50","author":"Poynard","year":"2004","journal-title":"Clin Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0186660","DOI":"10.1371\/journal.pone.0186660","article-title":"Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis","volume":"12","author":"Xiao","year":"2017","journal-title":"PLoS ONE."},{"key":"B5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1440-1746.2010.06612.x","article-title":"Biomarkers of liver fibrosis","volume":"26","author":"Adams","year":"2011","journal-title":"J Gastroenterol Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.autrev.2016.01.017","article-title":"Autoantibody production in cancer\u2013the humoral immune response toward autologous antigens in cancer patients","volume":"15","author":"Zaenker","year":"2016","journal-title":"Autoimmun Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.trecan.2017.02.003","article-title":"Autoantibodies: opportunities for early cancer detection","volume":"3","author":"Macdonald","year":"2017","journal-title":"Trends Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/pr3011342","article-title":"Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis","volume":"12","author":"Peng","year":"2013","journal-title":"J Proteome Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ebiom.2015.03.010","article-title":"An analysis of immunoreactive signatures in early stage hepatocellular carcinoma","volume":"2","author":"Hong","year":"2015","journal-title":"EBioMedicine."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.3892\/mmr.2016.5740","article-title":"Identification and clinical significance of an elevated level of serum aminoacylase-1 autoantibody in patients with hepatitis B virus-related liver cirrhosis","volume":"14","author":"He","year":"2016","journal-title":"Mol Med Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/hep.510310136","article-title":"Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond","volume":"31","author":"Brunt","year":"2000","journal-title":"Hepatology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cells8111423","article-title":"Metabolic signature of hepatic fibrosis: from individual pathways to systems biology","author":"Chang","year":"2019","journal-title":"Cells."},{"key":"B15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1517\/17530050902832848","article-title":"Detecting tumor-specific autoantibodies for cancer diagnosis: a technology overview","volume":"3","author":"Dudas","year":"2009","journal-title":"Expert Opin Med Diagn."},{"key":"B16","doi-asserted-by":"publisher","first-page":"111315","DOI":"10.1016\/j.bios.2019.111315","article-title":"Autoantibodies as diagnostic and prognostic cancer biomarker: Detection techniques and approaches","volume":"139","author":"Yadav","year":"2019","journal-title":"Biosens Bioelectron."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1080\/15384101.2018.1557496","article-title":"Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling","volume":"17","author":"Shahid","year":"2018","journal-title":"Cell Cycle."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3389\/fphys.2018.01019","article-title":"Dysfunction of sister chromatids separation promotes progression of hepatocellular carcinoma according to analysis of gene expression profiling","volume":"9","author":"Sun","year":"2018","journal-title":"Front Physiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e43223","DOI":"10.1371\/journal.pone.0043223","article-title":"Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS ONE."},{"key":"B20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.bbrc.2013.06.021","article-title":"Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma","volume":"436","author":"Dai","year":"2013","journal-title":"Biochem Biophys Res Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/cas.14037","article-title":"Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression","volume":"110","author":"Yang","year":"2019","journal-title":"Cancer Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.semarthrit.2020.06.010","article-title":"Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study","volume":"50","author":"Lourido","year":"2020","journal-title":"Semin Arthritis Rheum."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3389\/fonc.2020.01081","article-title":"Identification and validation of novel serum autoantibody biomarkers for early detection of colorectal cancer and advanced adenoma","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canep.2011.04.001","article-title":"Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system","volume":"36","author":"Liu","year":"2012","journal-title":"Cancer Epidemiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.chembiol.2019.09.009","article-title":"Family-wide Annotation of Enzymatic Pathways by Parallel In Vivo Metabolomics","volume":"26","author":"Kim","year":"2019","journal-title":"Cell Chem Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2014.05.001","article-title":"Proteomics-based identification of the tumor suppressor role of aminoacylase 1 in hepatocellular carcinoma","volume":"351","author":"Wei","year":"2014","journal-title":"Cancer Lett."},{"key":"B27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/carcin\/bgn255","article-title":"Genome-wide analysis identifies a tumor suppressor role for aminoacylase 1 in iron-induced rat renal cell carcinoma","volume":"30","author":"Zhong","year":"2009","journal-title":"Carcinogenesis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/ijc.25798","article-title":"Differential aminoacylase expression in neuroblastoma","volume":"129","author":"Long","year":"2011","journal-title":"Int J Cancer."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.humpath.2012.09.015","article-title":"Overexpression of aminoacylase 1 is associated with colorectal cancer progression","volume":"44","author":"Shi","year":"2013","journal-title":"Hum Pathol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000324597","article-title":"Differential kidney proteome profiling in a murine model of renal fibrosis under treatment with mycophenolate mofetil","volume":"78","author":"Petrova","year":"2011","journal-title":"Pathobiology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1471-2407-13-161","article-title":"A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values","volume":"13","author":"Jin","year":"2013","journal-title":"BMC Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1021\/pr200482t","article-title":"iTRAQ-2DLC-ESI-MS\/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma","volume":"10","author":"Jin GZ Li","year":"2011","journal-title":"J Proteome Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.807087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T03:04:53Z","timestamp":1641265493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.807087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":32,"alternative-id":["10.3389\/fmed.2021.807087"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.807087","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"article-number":"807087"}}